HSP90AA1 and plasma cell myeloma: A study on myeloma cell lines showed that KW-2478, a novel non-purine analogue antagonist, induced growth inhibition and apoptosis associated with Hsp90 client protein depletion [15], and combination with bortezomib exhibited synergistic activity in vitro and in vivo [190].